Page 127 - 中国全科医学2022-21

·2684· http://www.chinagp.net E-mail:zgqkyx@chinagp.net.cn

［7］WIVIOTT S D，RAZ I，BONACA M P，et al. Dapagliflozin and 2 diabetes：a systematic review and meta-analysis［J］. Lancet
cardiovascular outcomes in type 2 diabetes［J］. N Engl J Med， Diabetes Endocrinol，2019，7（11）：845-854. DOI：10.1016/
2019，380（4）：347-357. DOI：10.1056/NEJMoa1812389. S2213-8587（19）30256-6.
［8］CANNON C P，PRATLEY R，DAGOGO-JACK S，et al. ［20］SHIM C Y，SEO J，CHO I，et al. Randomized，controlled trial
Cardiovascular outcomes with ertugliflozin in type 2 diabetes［J］. to evaluate the effect of dapagliflozin on left ventricular diastolic
N Engl J Med，2020，383（15）：1425-1435. DOI： function in patients with type 2 diabetes mellitus：the IDDIA
10.1056/NEJMoa2004967. trial［J］. Circulation，2021，143（5）：510-512. DOI：
［9］BHATT D L，SZAREK M，PITT B，et al. Sotagliflozin in patients 10.1161/CIRCULATIONAHA.120.051992.
with diabetes and chronic kidney disease［J］. N Engl J Med， ［21］DÍAZ-RODRÍGUEZ E，AGRA R M，FERNÁNDEZ Á L，et al.
2021，384（2）：129-139. DOI：10.1056/NEJMoa2030186. Effects of dapagliflozin on human epicardial adipose tissue：
［10］ZANNAD F，COWIE M R. VERTIS-CV：more evidence that modulation of insulin resistance，inflammatory chemokine
sodium glucose cotransporter 2 inhibition brings rapid and sustained production，and differentiation ability［J］. Cardiovasc Res，
heart failure benefit［J］. Circulation，2020，142（23）：2216- 2018，114（2）：336-346. DOI：10.1093/cvr/cvx186.
2218. DOI：10.1161/CIRCULATIONAHA.120.050512. ［22］MAZIDI M，REZAIE P，GAO H K，et al. Effect of sodium-
［11］KRAMER C K，YE C，CAMPBELL S，et al. Comparison of new glucose cotransport-2 inhibitors on blood pressure in people
glucose-lowering drugs on risk of heart failure in type 2 diabetes：a with type 2 diabetes mellitus：a systematic review and meta-
network meta-analysis［J］. JACC Heart Fail，2018，6（10）： analysis of 43 randomized control trials with 22 528 patients［J］.
823-830. DOI：10.1016/j.jchf.2018.05.021. J Am Heart Assoc，2017，6（6）：e004007. DOI：
［12］GRANT P J，COSENTINO F. The 2019 ESC Guidelines on 10.1161/JAHA.116.004007.
diabetes，pre-diabetes，and cardiovascular diseases developed ［23］MCMURRAY J J V，SOLOMON S D，INZUCCHI S E，et al.
in collaboration with the EASD：new features and the‘Ten Dapagliflozin in patients with heart failure and reduced ejection
Commandments'of the 2019 Guidelines are discussed by Professor fraction［J］. N Engl J Med，2019，381（21）：1995-2008.
Peter J. Grant and Professor Francesco Cosentino，the Task Force DOI：10.1056/NEJMoa1911303.
chairmen［J］. Eur Heart J，2019，40（39）：3215-3217. ［24］SCHNEIDER M P，RAFF U，KOPP C，et al. Skin sodium
DOI：10.1093/eurheartj/ehz687. concentration correlates with left ventricular hypertrophy in
［13］PACKER M，BUTLER J，ZANNAD F，et al. Effect of CKD［J］. J Am Soc Nephrol，2017，28（6）：1867-1876.
empagliflozin on worsening heart failure events in patients with DOI：10.1681/ASN.2016060662.
heart failure and preserved ejection fraction：emperor-preserved ［25］LAMBERS HEERSPINK H J，DE ZEEUW D，WIE L，et al.
trial［J］. Circulation，2021，144（16）：1284-1294. DOI： Dapagliflozin a glucose-regulating drug with diuretic properties in
10.1161/CIRCULATIONAHA.121.056824. subjects with type 2 diabetes［J］. Diabetes Obes Metab，2013，15
［14］DEWAN P，SOLOMON S D，JHUND P S，et al. Efficacy and （9）：853-862. DOI：10.1111/dom.12127.
safety of sodium-glucose co-transporter 2 inhibition according to left ［26］HALLOW K M，HELMLINGER G，GREASLEY P J，et al.
ventricular ejection fraction in DAPA-HF［J］. Eur J Heart Fail， Why do SGLT2 inhibitors reduce heart failure hospitalization?
2020，22（7）：1247-1258. DOI：10.1002/ejhf.1867. A differential volume regulation hypothesis［J］. Diabetes Obes
［15］BHATT D L，SZAREK M，STEG P G，et al. Sotagliflozin in Metab，2018，20（3）：479-487. DOI：10.1111/dom.13126.
patients with diabetes and recent worsening heart failure［J］. ［27］LOPASCHUK G D，USSHER J R，FOLMES C D，et al. Myocardial
N E ng l J M e d，2021，384（2）：117-128. DOI： fatty acid metabolism in health and disease［J］. Physiol Rev，
10.1056/NEJMoa2030183. 2010，90（1）：207-258. DOI：10.1152/physrev.00015.2009.
［16］SOLOMON S D，CLAGGETT B，LEWIS E F，et al. Influence ［28］ZHANG L Y，JASWAL J S，USSHER J R，et al. Cardiac insulin-
of ejection fraction on outcomes and efficacy of spironolactone in resistance and decreased mitochondrial energy production precede
patients with heart failure with preserved ejection fraction［J］. Eur the development of systolic heart failure after pressure-overload
Heart J，2016，37（5）：455-462. DOI：10.1093/eurheartj/ hypertrophy［J］. Circ Heart Fail，2013，6（5）：1039-1048.
ehv464. ［29］NEUBAUER S. The failing heart—an engine out of fuel［J］.
［17］SOLOMON S D，DE BOER R A，DEMETS D，et al. Dapagliflozin N Engl J Med，2007，356（11）：1140-1151.
in heart failure with preserved and mildly reduced ejection fraction： ［30］ABOUEZZEDDINE O F，KEMP B J，BORLAUG B A，et al.
rationale and design of the DELIVER trial［J］. Eur J Heart Fail， Myocardial energetics in heart failure with preserved ejection
2021，23（7）：1217-1225. DOI：10.1002/ejhf.2249. fraction［J］. Circ Heart Fail，2019，12（10）：e006240.
［18］LEE M M Y，BROOKSBANK K J M，WETHERALL K，et al. DOI：10.1161/CIRCHEARTFAILURE.119.006240.
Effect of empagliflozin on left ventricular volumes in patients with ［31］DICK S A，EPELMAN S. Chronic heart failure and inflammation：
type 2 diabetes，or prediabetes，and heart failure with reduced what do we really know? ［J］. Circ Res，2016，119（1）：159-
ejection fraction （SUGAR-DM-HF）［J］. Circulation， 176. DOI：10.1161/CIRCRESAHA.116.308030.
2021，143（6）：516-525. DOI：10.1161/CIRCULATIONA ［32］BRIASOULIS A，ANDROULAKIS E，CHRISTOPHIDES T，
HA.120.052186. et al. The role of inflammation and cell death in the pathogenesis，
［19］NEUEN B L，YOUNG T，HEERSPINK H J L，et al. SGLT2 progression and treatment of heart failure［J］. Heart Fail Rev，
inhibitors for the prevention of kidney failure in patients with type 2016，21（2）：169-176. DOI：10.1007/s10741-016-9533-z.